Breaking News Instant updates and real-time market news.

SHAK

Shake Shack

$96.29 /

+18.115 (+23.17%)

12:00
11/05/21
11/05
12:00
11/05/21
12:00

Shake Shack rises 22.8%

Shake Shack is up 22.8%, or $17.77 to $95.85.

  • 17

    Nov

SHAK Shake Shack
$96.29 /

+18.115 (+23.17%)

11/05/21 BTIG
Shake Shack upgraded to Buy from Neutral at BTIG
11/05/21 BTIG
Shake Shack upgraded to Buy from Neutral at BTIG
11/03/21 Northcoast
Shake Shack upgraded to Buy on stronger October sales at Northcoast
11/03/21 Northcoast
Shake Shack upgraded to Buy from Neutral at Northcoast

TODAY'S FREE FLY STORIES

Recommendations
Sellas Life Sciences price target lowered to $16 from $18 at Cantor Fitzgerald » 07:27
12/03/21
12/03
07:27
12/03/21
07:27
SLS

Sellas Life Sciences

$6.42 /

+0.08 (+1.26%)

Cantor Fitzgerald analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SLS Sellas Life Sciences
$6.42 /

+0.08 (+1.26%)

SLS Sellas Life Sciences
$6.42 /

+0.08 (+1.26%)

07/21/21 Cantor Fitzgerald
Sellas Life Sciences initiated with an Overweight at Cantor Fitzgerald
07/21/21 Cantor Fitzgerald
Sellas Life Sciences initiated with an Overweight at Cantor Fitzgerald
06/25/21 Maxim
Sellas Life Sciences price target raised to $21 from $12 at Maxim
06/03/21 Alliance Global Partners
Sellas Life Sciences price target raised to $16.50 from $8 at Alliance Global Partners
SLS Sellas Life Sciences
$6.42 /

+0.08 (+1.26%)

Periodicals
Credit Suisse plans to restructure banker pay, Bloomberg reports » 07:25
12/03/21
12/03
07:25
12/03/21
07:25
CS

Credit Suisse

$9.72 /

+0.22 (+2.32%)

Credit Suisse chairman…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CS Credit Suisse
$9.72 /

+0.22 (+2.32%)

CS Credit Suisse
$9.72 /

+0.22 (+2.32%)

11/16/21 JPMorgan
Credit Suisse downgraded to Underweight on new strategy at JPMorgan
11/16/21 JPMorgan
Credit Suisse downgraded to Underweight from Neutral at JPMorgan
11/15/21 Morgan Stanley
Credit Suisse price target raised to CHF 12 from CHF 11 at Morgan Stanley
11/09/21 Keefe Bruyette
Credit Suisse downgraded to Market Perform from Outperform at Keefe Bruyette
CS Credit Suisse
$9.72 /

+0.22 (+2.32%)

CS Credit Suisse
$9.72 /

+0.22 (+2.32%)

CS Credit Suisse
$9.72 /

+0.22 (+2.32%)

CS Credit Suisse
$9.72 /

+0.22 (+2.32%)

Upgrade
Tisco Financial upgraded to Overweight from Neutral at JPMorgan » 07:25
12/03/21
12/03
07:25
12/03/21
07:25
TICSF

Tisco Financial

/

+

JPMorgan analyst Harsh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 07:25
12/03/21
12/03
07:25
12/03/21
07:25
MRVL

Marvell

$71.02 /

+0.18 (+0.25%)

Technology Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

07:14 Today BMO Capital
Marvell price target raised to $98 from $85 at BMO Capital
07:10 Today Goldman Sachs
Goldman admits to being wrong to stay on sidelines, upgrades Marvell to Buy
07:06 Today Goldman Sachs
Marvell upgraded to Buy from Neutral at Goldman Sachs
06:49 Today UBS
Marvell price target raised to $95 from $87 at UBS
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

Recommendations
Toronto-Dominion price target raised to C$102.50 from C$96.50 at Canaccord » 07:24
12/03/21
12/03
07:24
12/03/21
07:24
TD

Toronto-Dominion

$75.33 /

+3.58 (+4.99%)

Canaccord analyst Scott…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TD Toronto-Dominion
$75.33 /

+3.58 (+4.99%)

TD Toronto-Dominion
$75.33 /

+3.58 (+4.99%)

11/23/21 Scotiabank
Toronto-Dominion price target raised to C$104 from C$94 at Scotiabank
11/22/21 BofA
BofA lists three reasons to double upgrade Toronto-Dominion to Buy
11/22/21 BofA
Toronto-Dominion upgraded to Buy from Underperform at BofA
10/01/21 National Bank
Toronto-Dominion upgraded to Outperform from Sector Perform at National Bank
TD Toronto-Dominion
$75.33 /

+3.58 (+4.99%)

TD Toronto-Dominion
$75.33 /

+3.58 (+4.99%)

TD Toronto-Dominion
$75.33 /

+3.58 (+4.99%)

Upgrade
Singapore Exchange upgraded to Overweight from Neutral at JPMorgan » 07:24
12/03/21
12/03
07:24
12/03/21
07:24
SPXCF

Singapore Exchange

$6.60 /

-0.02 (-0.30%)

JPMorgan analyst Harsh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPXCF Singapore Exchange
$6.60 /

-0.02 (-0.30%)

08/24/21 Credit Suisse
Singapore Exchange downgraded to Underperform from Neutral at Credit Suisse
08/22/21 Goldman Sachs
Singapore Exchange downgraded to Neutral from Buy at Goldman Sachs
Upgrade
OCBC upgraded to Overweight from Neutral at JPMorgan » 07:23
12/03/21
12/03
07:23
12/03/21
07:23
OVCHY

OCBC

$16.49 /

+0.25 (+1.54%)

JPMorgan analyst Harsh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OVCHY OCBC
$16.49 /

+0.25 (+1.54%)

04/06/21 Goldman Sachs
OCBC upgraded to Buy from Neutral at Goldman Sachs
03/10/21 JPMorgan
OCBC upgraded to Overweight from Neutral at JPMorgan
Initiation
International Container Terminal initiated with an Overweight at JPMorgan » 07:22
12/03/21
12/03
07:22
12/03/21
07:22
ICTEF

International Container Terminal Services

$3.90 /

+ (+0.00%)

JPMorgan analyst Shawn Ng…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Initiation
Cardiol Therapeutics initiated with a Buy at Canaccord » 07:22
12/03/21
12/03
07:22
12/03/21
07:22
CRDL

Cardiol Therapeutics

$2.02 /

+0.155 (+8.33%)

Canaccord analyst Edward…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

08/25/21 Raymond James
Cardiol Therapeutics price target raised to C$5 from C$4.50 at Raymond James
08/24/21 Raymond James
Raymond James ups Cardiol target to C$5 after FDA clears Phase II study
  • 03
    Nov
CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

CRDL Cardiol Therapeutics
$2.02 /

+0.155 (+8.33%)

Recommendations
Citi opens 'positive catalyst watch' on Stellantis into software day » 07:21
12/03/21
12/03
07:21
12/03/21
07:21
STLA

Stellantis

$18.15 /

+0.455 (+2.57%)

Citi analyst Gabriel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
STLA Stellantis
$18.15 /

+0.455 (+2.57%)

STLA Stellantis
$18.15 /

+0.455 (+2.57%)

11/29/21 Citi
Stellantis resumed with a Buy at Citi
11/02/21 Nomura
Nomura downgrades Ford to Reduce, calls premium valuation 'hard to justify'
09/07/21 KeyBanc
Jeep micro site on Amazon points to auto sales moving online, says KeyBanc
09/03/21 Deutsche Bank
Stellantis deal 'significant opportunity' for Open Lending, says Deutsche Bank
STLA Stellantis
$18.15 /

+0.455 (+2.57%)

STLA Stellantis
$18.15 /

+0.455 (+2.57%)

STLA Stellantis
$18.15 /

+0.455 (+2.57%)

Downgrade
TopBuild downgraded to Neutral from Buy at BTIG » 07:19
12/03/21
12/03
07:19
12/03/21
07:19
BLD

TopBuild

$276.83 /

+12.445 (+4.71%)

BTIG analyst Ryan Gilbert…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BLD TopBuild
$276.83 /

+12.445 (+4.71%)

BLD TopBuild
$276.83 /

+12.445 (+4.71%)

11/03/21 Truist
TopBuild price target raised to $300 from $253 at Truist
10/21/21 BTIG
TopBuild price target raised to $292 from $271 at BTIG
09/10/21 JPMorgan
TopBuild price target raised to $264 from $246 at JPMorgan
09/09/21
Fly Intel: Top five analyst upgrades
BLD TopBuild
$276.83 /

+12.445 (+4.71%)

Downgrade
DocuSign downgraded to Hold from Buy at Needham » 07:18
12/03/21
12/03
07:18
12/03/21
07:18
DOCU

DocuSign

/

+

Needham analyst Scott…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DOCU DocuSign
/

+

DOCU DocuSign
/

+

07:08 Today Baird
DocuSign price target lowered to $220 from $330 at Baird
06:36 Today Wedbush
DocuSign downgraded to Neutral from Outperform at Wedbush
06:36 Today JMP Securities
DocuSign price target lowered to $307 from $320 at JMP Securities
06:17 Today Citi
DocuSign price target lowered to $231 from $389 at Citi
DOCU DocuSign
/

+

DOCU DocuSign
/

+

DOCU DocuSign
/

+

DOCU DocuSign
/

+

Recommendations
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald » 07:18
12/03/21
12/03
07:18
12/03/21
07:18
CRVS

Corvus Pharmaceuticals

$3.31 /

+0.05 (+1.53%)

, AZN

AstraZeneca

$54.78 /

-0.1 (-0.18%)

Cantor Fitzgerald analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
08/03/21 Mizuho
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

  • 12
    Feb
AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

CRVS Corvus Pharmaceuticals
$3.31 /

+0.05 (+1.53%)

AZN AstraZeneca
$54.78 /

-0.1 (-0.18%)

Upgrade
Citi upgrades Upstart to Buy on resumption after 55% selloff » 07:18
12/03/21
12/03
07:18
12/03/21
07:18
UPST

Upstart

$176.65 /

-3.1 (-1.72%)

Citi analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UPST Upstart
$176.65 /

-3.1 (-1.72%)

UPST Upstart
$176.65 /

-3.1 (-1.72%)

07:05 Today Citi
Upstart upgraded to Buy from Neutral at Citi
11/10/21 Piper Sandler
Upstart should be bought on earnings selloff, says Piper Sandler
10/26/21
Fly Intel: Top five analyst downgrades
10/26/21 Jefferies
Jefferies downgrades Upstart to Hold, doubles target to $330
UPST Upstart
$176.65 /

-3.1 (-1.72%)

  • 16
    Jun
  • 09
    Apr
  • 16
    Dec
UPST Upstart
$176.65 /

-3.1 (-1.72%)

UPST Upstart
$176.65 /

-3.1 (-1.72%)

Hot Stocks
Hagerty to begin trading on NYSE on December 3 » 07:17
12/03/21
12/03
07:17
12/03/21
07:17
HGTY

Hagerty

$10.89 /

+0.735 (+7.24%)

, ADF

Aldel Financial

/

+

Hagerty (HGTY) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HGTY Hagerty
$10.89 /

+0.735 (+7.24%)

ADF Aldel Financial
/

+

Recommendations
Marvell price target raised to $98 from $85 at BMO Capital » 07:14
12/03/21
12/03
07:14
12/03/21
07:14
MRVL

Marvell

$71.02 /

+0.18 (+0.25%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

07:10 Today Goldman Sachs
Goldman admits to being wrong to stay on sidelines, upgrades Marvell to Buy
07:06 Today Goldman Sachs
Marvell upgraded to Buy from Neutral at Goldman Sachs
06:49 Today UBS
Marvell price target raised to $95 from $87 at UBS
06:38 Today Credit Suisse
Marvell price target raised to $105 from $85 at Credit Suisse
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

Recommendations
Kroger price target raised to $41 from $39 at BMO Capital » 07:11
12/03/21
12/03
07:11
12/03/21
07:11
KR

Kroger

$44.61 /

+4.4 (+10.94%)

BMO Capital analyst Kelly…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KR Kroger
$44.61 /

+4.4 (+10.94%)

KR Kroger
$44.61 /

+4.4 (+10.94%)

06:43 Today Deutsche Bank
Kroger price target raised to $45 from $43 at Deutsche Bank
06:28 Today Citi
Kroger price target raised to $47 from $43 at Citi
06:14 Today Barclays
Kroger price target raised to $38 from $37 at Barclays
11/03/21 Loop Capital
Loop Capital cuts Bed Bath & Beyond to Sell, cites deterioration in relevance
KR Kroger
$44.61 /

+4.4 (+10.94%)

KR Kroger
$44.61 /

+4.4 (+10.94%)

KR Kroger
$44.61 /

+4.4 (+10.94%)

KR Kroger
$44.61 /

+4.4 (+10.94%)

Hot Stocks
Xenon Pharmaceuticals presents additional data from Phase 2b X-TOLE trial » 07:10
12/03/21
12/03
07:10
12/03/21
07:10
XENE

Xenon Pharmaceuticals

$25.89 /

+0.065 (+0.25%)

Xenon Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$25.89 /

+0.065 (+0.25%)

XENE Xenon Pharmaceuticals
$25.89 /

+0.065 (+0.25%)

11/11/21 SVB Leerink
Xenon Pharmaceuticals price target raised to $40 from $34 at SVB Leerink
10/28/21 RBC Capital
Xenon Pharmaceuticals initiated with an Outperform at RBC Capital
10/06/21 Wedbush
Wedbush remains bullish on Xenon as financing gives firepower to advance XEN1101
10/04/21 Jefferies
Jefferies ups Xenon target to $50 after 'home run' epilepsy data
XENE Xenon Pharmaceuticals
$25.89 /

+0.065 (+0.25%)

  • 06
    Oct
  • 10
    Mar
XENE Xenon Pharmaceuticals
$25.89 /

+0.065 (+0.25%)

Upgrade
Goldman admits to being wrong to stay on sidelines, upgrades Marvell to Buy » 07:10
12/03/21
12/03
07:10
12/03/21
07:10
MRVL

Marvell

$71.02 /

+0.18 (+0.25%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

07:06 Today Goldman Sachs
Marvell upgraded to Buy from Neutral at Goldman Sachs
06:49 Today UBS
Marvell price target raised to $95 from $87 at UBS
06:38 Today Credit Suisse
Marvell price target raised to $105 from $85 at Credit Suisse
06:36 Today Citi
Marvell price target raised to $87 from $70 at Citi
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

Recommendations
Veeva price target lowered to $310 from $349 at Baird » 07:10
12/03/21
12/03
07:10
12/03/21
07:10
VEEV

Veeva

$262.17 /

-10.09 (-3.71%)

Baird analyst Joe Vruwink…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VEEV Veeva
$262.17 /

-10.09 (-3.71%)

VEEV Veeva
$262.17 /

-10.09 (-3.71%)

12/02/21 Needham
Veeva price target lowered to $327 from $385 at Needham
12/02/21 Baird
Veeva price target lowered to $310 from $349 at Baird
12/02/21 UBS
Veeva price target lowered to $290 from $320 at UBS
10/01/21 Stifel
Veeva assumed with a Buy at Stifel
VEEV Veeva
$262.17 /

-10.09 (-3.71%)

VEEV Veeva
$262.17 /

-10.09 (-3.71%)

VEEV Veeva
$262.17 /

-10.09 (-3.71%)

Recommendations
DocuSign price target lowered to $220 from $330 at Baird » 07:08
12/03/21
12/03
07:08
12/03/21
07:08
DOCU

DocuSign

$233.83 /

+2.77 (+1.20%)

Baird analyst William…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

06:36 Today Wedbush
DocuSign downgraded to Neutral from Outperform at Wedbush
06:36 Today JMP Securities
DocuSign price target lowered to $307 from $320 at JMP Securities
06:17 Today Citi
DocuSign price target lowered to $231 from $389 at Citi
04:47 Today Piper Sandler
DocuSign downgraded to Neutral from Overweight at Piper Sandler
DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

DOCU DocuSign
$233.83 /

+2.77 (+1.20%)

Hot Stocks
Aclaris Therapeutics publishes preclinical research on zunsemetinib » 07:06
12/03/21
12/03
07:06
12/03/21
07:06
ACRS

Aclaris Therapeutics

$12.64 /

+0.07 (+0.56%)

Aclaris Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$12.64 /

+0.07 (+0.56%)

ACRS Aclaris Therapeutics
$12.64 /

+0.07 (+0.56%)

07/23/21 Jefferies
Aclaris Therapeutics assumed with a Buy at Jefferies
06/16/21 H.C. Wainwright
Aclaris Therapeutics price target raised to $50 from $40 at H.C. Wainwright
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Piper Sandler
Aclaris Therapeutics initiated with an Overweight at Piper Sandler
ACRS Aclaris Therapeutics
$12.64 /

+0.07 (+0.56%)

  • 10
    Jun
  • 20
    Jan
ACRS Aclaris Therapeutics
$12.64 /

+0.07 (+0.56%)

Upgrade
Marvell upgraded to Buy from Neutral at Goldman Sachs » 07:06
12/03/21
12/03
07:06
12/03/21
07:06
MRVL

Marvell

$71.02 /

+0.18 (+0.25%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

06:49 Today UBS
Marvell price target raised to $95 from $87 at UBS
06:38 Today Credit Suisse
Marvell price target raised to $105 from $85 at Credit Suisse
06:36 Today Citi
Marvell price target raised to $87 from $70 at Citi
06:10 Today Deutsche Bank
Marvell price target raised to $100 from $76 at Deutsche Bank
MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

MRVL Marvell
$71.02 /

+0.18 (+0.25%)

Recommendations
GMS Inc. price target raised to $68 from $62 at Baird » 07:05
12/03/21
12/03
07:05
12/03/21
07:05
GMS

GMS Inc.

$57.74 /

+1.36 (+2.41%)

Baird analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GMS GMS Inc.
$57.74 /

+1.36 (+2.41%)

GMS GMS Inc.
$57.74 /

+1.36 (+2.41%)

06:14 Today Barclays
GMS Inc. price target raised to $61 from $56 at Barclays
09/08/21 Barclays
GMS Inc. price target raised to $56 from $49 at Barclays
09/03/21 Truist
GMS Inc. price target raised to $62 from $52 at Truist
09/03/21 Baird
GMS Inc. price target raised to $62 from $58 at Baird
GMS GMS Inc.
$57.74 /

+1.36 (+2.41%)

GMS GMS Inc.
$57.74 /

+1.36 (+2.41%)

Upgrade
Upstart upgraded to Buy from Neutral at Citi » 07:05
12/03/21
12/03
07:05
12/03/21
07:05
UPST

Upstart

$176.65 /

-3.1 (-1.72%)

Citi analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UPST Upstart
$176.65 /

-3.1 (-1.72%)

UPST Upstart
$176.65 /

-3.1 (-1.72%)

11/10/21 Piper Sandler
Upstart should be bought on earnings selloff, says Piper Sandler
10/26/21
Fly Intel: Top five analyst downgrades
10/26/21 Jefferies
Jefferies downgrades Upstart to Hold, doubles target to $330
10/26/21 Jefferies
Upstart downgraded to Hold from Buy at Jefferies
UPST Upstart
$176.65 /

-3.1 (-1.72%)

  • 16
    Jun
  • 09
    Apr
  • 16
    Dec
UPST Upstart
$176.65 /

-3.1 (-1.72%)

UPST Upstart
$176.65 /

-3.1 (-1.72%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.